US trade agreement threatens to increase drug prices and withhold safety dataBMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6908 (Published 15 November 2013) Cite this as: BMJ 2013;347:f6908
- Deborah Cohen
Campaign groups have criticized the US government of “shameful bullying on behalf of the giant drug companies” during trade negotiations between the United States and 11 Asian and Latin American countries in the so called Trans-Pacific Partnership.
Draft text from the secretive trade rounds published on WikiLeaks focus on intellectual property, an area of law affecting areas as diverse as pharmaceuticals and civil liberties.1 The leak came ahead of another meeting on the agreement in Salt Lake City next week.
The trade agreement includes proposals for more than a dozen measures that would limit competition and raise drug prices.
The US watchdog group Public Citizen said that the text showed that a US representative was pressing the other negotiating countries “to expand pharmaceutical monopoly protections and trade away …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial